Pro-inflammatory cytokine genes influence the clinical features of frontotemporal lobar degeneration

Dementia and Geriatric Cognitive Disorders

Volumn 27, Issue 6, 2009, Pages 543-547

  Rainero, Innocenzo ^a   Rubino, Elisa ^a   Cappa, Giorgetta ^a   Rota, Eugenia ^a   Valfrè, Walter ^a   Ferrero, Patrizia ^a   Fenoglio, Pierpaola ^a   Baci, Denisa ^a   D'Amico, Giuseppina ^a   Vaula, Giovanna ^a   Gallone, Salvatore ^a   Pinessi, Lorenzo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Frontotemporal lobar degeneration; Interleukin 1 ; Interleukin 1 ; Interleukin 6; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FRONTOTEMPORAL DEMENTIA; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; ONSET AGE; PRIORITY JOURNAL;

AGE OF ONSET; AGED; ALLELES; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; CYTOKINES; DEMENTIA; DISEASE PROGRESSION; DNA; FEMALE; GENOTYPE; HUMANS; INFLAMMATION; INTERLEUKINS; ITALY; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67449141574     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000225962     Document Type: Article

References (36)

1. Snowden JS, Neary D, Mann DM:Fronto-temporal dementia. Br J Psychiatry 2002;180:140-143.
2. Tissot R, Constantinidis J, Richard J:Pick's disease;in Bruyn V (ed):Handbook of Clinical Neurology. Amsterdam, North-Holland Publishing Company, 1985, pp 233-246.
3. Ratnavalli E, Brayne C, Dawson K, Hodges JR:The prevalence of frontotemporal dementia. Neurology 2002;58:1615-1621.
4. Van der Zee J, Gijselinck I, Pirici D, Kumar-Singh S, Cruts M, Van Broeckhoven C: Fron-totemporal lobar degeneration with ubiquitin-positive inclusions:a molecular genetic update. Neurodegenerative Dis 2007;4:227- 235.
5. Guyant-Maréchal L, Laquerrière A, Duyckaerts C, Dumanchin C, Bou J, Dugny F, Le Ber I, Frébourg T, Hannequin D, Campion D:Valosin-containing protein gene mutations:clinical and neuropathologic features. Neurology 2006;67:644-651.
6. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM:Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007;53:337-351.
7. Cagnin A, Rossor M, Sampson EL, Mackinnon T, Banati RB:In vivo detection of microglial activation in frontotemporal dementia. Ann Neurol 2004;56:894-897.
8. Ahmed Z, Mackenzie IR, Hutton ML, Dickson DW:Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation 2007;11:4-7.
9. Sjogren M, Folkesson S, Blennow K, Tar-kowski E:Increased intrathecal inflammatory activity in frontotemporal dementia:pathophysiological implications. J Neurol Neurosurg Psychiatry 2004;75:1107-1111.
10. Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Venturelli E, Pijnenburg YA, Bresolin N, Scarpini E:Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2006;66:146-147.
11. Galimberti D, Venturelli E, Fenoglio C, Guidi I, Villa C, Bergamaschini L, Cortini F, Scalabrini D, Baron P, Vergani C, Bresolin N, Scarpini E: Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and fronto-temporal lobar degeneration. J Neurol 2008;255:539-544.
12. Shirodaria S, Smith J, McKay IJ, Kennett CN, Hughes FJ: Polymorphisms in the IL-1A gene are correlated with levels of interleukin-1alpha protein in gingival cervicular fluid of teeth with severe periodontal disease. J Dent Res 2000;79:1864-1869.
13. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P:The effect of novel polymorphisms in the inter-leukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-1376.
14. Hajeer AH, Hutchinson IV: Influence of TNFalpha gene polymorphisms on TNF-alpha production and disease. Hum Immunol 2001;62:1191-1199.
15. McGeer PL, McGeer EG: Polymorphisms in inflammatory genes and the risk of Alzheimer disease. Arch Neurol 2001;58:1790-1792.
16. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF:Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-1554.
17. Folstein MF, Folstein SE, McHugh PR:'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. Psychiatr Res 1995;12:189-198.
18. Dubois B, Slachevsky A, Litvan I, Pillon B: The FAB:a Frontal Assessment Battery at bedside. Neurology 2000;55:1621-1626.
19. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
20. Katz S, Downs TD, Cash HR, Grotz RC: Progress in the development of the index of ADL. Gerontologist 1970;10:20-30.
21. Lawton MP, Brody EM:Assessment of older people:self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
22. Huang D, Zheng C, Giscombe R, Matell G, Pirskanen R, Lefvert AK: Polymorphism at -174 and in the 3′ flanking region of inter-leukin-6 (IL-6) gene in patients with myasthenia gravis. J Neuroimmunol 1999;101:197-200.
23. Keso T, Perola M, Laippala P, Ilveskoski E, Kunnas TA, Mikkelsson J, Penttilä A, Hurme M, Karhunen PJ: Polymorphisms within the tumor necrosis factor locus and prevalence of coronary artery disease in middle-aged men. Atherosclerosis 2001;154:691-697.
24. Wenham PR, Price WH, Blundel G:Apoli-poprotein E genotyping by one-stage PCR. Lancet 1991;337:1158-1159.
25. Bird TD, Jarvik GP, Wood NW:Genetic association studies:genes in search of diseases. Neurology 2001;57:1153-1154.
26. Tarkowski E:Cytokines in dementias. Curr Drug Targets Inflamm Allergy 2002;1:193- 200.
27. Stoll G, Jander S, Schroeter M:Cytokines in CNS disorders:neurotoxicity versus neuroprotection. J Neural Transm 2000;59 (suppl):81-89.
28. Sriram K, O'Callaghan JP: Divergent roles for tumor necrosis factor-alpha in the brain. J Neuroimmune Pharmacol 2007;2:14 0 - 153.
29. Basu A, Krady JK, Levison SW: Interleukin-1: a master regulator of neuroinflammation. J Neurosci Res 20 04;78:151-156.
30. Tanji K, Mori F, Imaizumi T, Yoshida H, Sa-toh K, Wakabayashi K: Interleukin-1 induces tau phosphorylation and morphological changes in cultured human astrocytes. Neuroreport 2003;14:413-417.
31. Iacoviello L, Di Castelnuovo A, Gattone M, Pezzini A, Assanelli D, Lorenzet R, Del Zot-to E, Colombo M, Napoleone E, Amore C, D'Orazio A, Padovani A, de Gaetano G, Giannuzzi P, Donati MB; IGIGI Investigators: Polymorphisms of the interleukin-1beta gene affect the risk of myocardial infarction and ischemic stroke at young age and the response of mononuclear cells to stimulation i n vitro. Ar terioscler Thromb Vasc Biol 20 05;25:222-227.
32. Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O'Banion MK:Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 2007;11 7:1483-1485.
33. Tsai SJ, Hong CJ, Liu ME, Hou SJ, Yen FC, Hsieh CH, Liou YJ:Interleukin-1 beta (C-511T) genetic polymorphism is associated with cognitive performance in elderly males without dementia. Neurobiol Aging 2008;Nov 13, Epub ahead of print.
34. Wright CB, Sacco RL, Rundek TR, Delman JB, Rabbani LE, Elkind MS: Interleukin-6 is associated with cognitive function:the Northern Manhattan Study. J Stroke Cere-brovasc Dis 2006;15:34-38.
35. Baune BT, Ponath G, Rothermundt M, Riess O, Funke H, Berger K:Association between genetic variants of IL-1beta, IL-6 and TNF-alpha cytokines and cognitive performance in the elderly general population of the MEMO-study. Psychoneuroendocrinology 2008;33:68-76.
36. Quintanilla RA, Orellana DI, González-Bil-lault C, Maccioni RB:Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res 2004;295:245-257.